Severe Aplastic Anemia
Feb 23, 2026
Bone Marrow Failure: The Silent Global Crisis Driving a New Era of Therapeutic Innovation
Summary In 2024, the 7MM reported approximately 35,000 incident BMF cases, highlighting the persistent clinical burden and the ongoing need for earlier diagnosis and more effective treatment strategies. ROMIPLATE has made notable regulatory progress in Japan, its only approved market for aplastic anemia, ex...
Read More...
Dec 09, 2025
Kallyope’s Elismetrep Achieves Primary and Secondary Endpoints in Phase 2b Clinical Study; IDEAYA Secures IND Approval to Initiate Clinical Evaluation of IDE034; OMISIRGE Receives FDA Approval; Agios Updates on Regulatory Path for Mitapivat to Treat Thalassemia; Mirum to Acquire Bluejay Therapeutics
Kallyope Reports Successful Phase 2b Trial Outcomes for Elismetrep in Acute Migraine Treatment Kallyope, a late-stage biotechnology company focused on neurological and metabolic therapies, announced positive results from its Phase 2b dose-ranging study of the lead candidate, elismetrep (K-304), for the acute tre...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
